{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,6]],"date-time":"2026-07-06T03:17:14Z","timestamp":1783307834886,"version":"3.54.6"},"update-to":[{"DOI":"10.1371\/journal.ppat.1013983","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000}}],"reference-count":63,"publisher":"Public Library of Science (PLoS)","issue":"3","license":[{"start":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T00:00:00Z","timestamp":1772409600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2023YFC2307602"],"award-info":[{"award-number":["2023YFC2307602"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272310"],"award-info":[{"award-number":["82272310"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82471861"],"award-info":[{"award-number":["82471861"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100016808","name":"Natural Science Foundation of Xiamen Municipality","doi-asserted-by":"publisher","award":["3502Z20227165"],"award-info":[{"award-number":["3502Z20227165"]}],"id":[{"id":"10.13039\/100016808","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720220004"],"award-info":[{"award-number":["20720220004"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["20720220006"],"award-info":[{"award-number":["20720220006"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plospathogens.org"],"crossmark-restriction":false},"short-container-title":["PLoS Pathog"],"abstract":"<jats:p>\n                    Varicella-zoster virus (VZV), the cause of shingles, remains a significant health issue worldwide, particularly among aging populations. The recombinant zoster vaccine (Shingrix, RZV) is the only approved vaccine in many countries and has demonstrated &gt;90% efficacy with durable protection lasting over a decade, highlighting the value of subunit vaccines targeting VZV glycoprotein E (VZV gE). Although RZV provides durable and highly effective protection, alternative vaccine platforms remain important for advancing antigen design and improving immune presentation. Advances in nanoparticle technology now enable antigens to be displayed in highly ordered, repetitive arrays, offering new opportunities to strengthen antiviral immunity. Here, we developed a novel nano-vaccine named Nano-gE\n                    <jats:sub>VZV<\/jats:sub>\n                    , which employs the antigen from the licensed Hepatitis E vaccine (Hecolin) as a nanoparticle scaffold and uses a nano-binder (NB) to display VZV gE in a repetitive arrangement. Nano-gE\n                    <jats:sub>VZV<\/jats:sub>\n                    demonstrates enhanced antigen uptake by antigen-presenting cells (APCs), improved lymph node retention, and stronger B- and T-cell responses compared with Shingrix in mouse models. While RZV remains the gold standard for herpes zoster prevention, we explored a nanoparticle-based gE display platform as a complementary approach to improve manufacturability and immune presentation.\n                  <\/jats:p>","DOI":"10.1371\/journal.ppat.1013983","type":"journal-article","created":{"date-parts":[[2026,3,2]],"date-time":"2026-03-02T18:38:09Z","timestamp":1772476689000},"page":"e1013983","update-policy":"https:\/\/doi.org\/10.1371\/journal.ppat.corrections_policy","source":"Crossref","is-referenced-by-count":1,"title":["A modular nanoparticle display strategy for varicella-zoster virus gE based on a licensed protein scaffold"],"prefix":"10.1371","volume":"22","author":[{"given":"Wenhui","family":"Xue","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yarong","family":"Zeng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingyan","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minqing","family":"Hong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huizheng","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuyun","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinjin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhenqin","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingbing","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hai","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rui","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lizhi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ying","family":"Gu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tingting","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ningshao","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3374-1038","authenticated-orcid":true,"given":"Shaowei","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,3,2]]},"reference":[{"issue":"11","key":"ppat.1013983.ref001","doi-asserted-by":"crossref","first-page":"609","DOI":"10.3390\/v10110609","article-title":"Clinical Features of Varicella-Zoster Virus Infection","volume":"10","author":"PGE Kennedy","year":"2018","journal-title":"Viruses"},{"key":"ppat.1013983.ref002","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1016\/B978-0-444-53488-0.00012-2","article-title":"Varicella-zoster","volume":"123","author":"D Gilden","year":"2014","journal-title":"Handb Clin Neurol"},{"issue":"10","key":"ppat.1013983.ref003","doi-asserted-by":"crossref","first-page":"4429","DOI":"10.1172\/JCI121484","article-title":"Th1 memory differentiates recombinant from live herpes zoster vaccines","volume":"128","author":"MJ Levin","year":"2018","journal-title":"J Clin Invest"},{"issue":"11","key":"ppat.1013983.ref004","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.1016\/S1474-4422(07)70267-3","article-title":"The neurotropic herpes viruses: herpes simplex and varicella-zoster","volume":"6","author":"I Steiner","year":"2007","journal-title":"Lancet Neurol"},{"issue":"6","key":"ppat.1013983.ref005","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1002\/jmv.27538","article-title":"The global disease burden of varicella-zoster virus infection from 1990 to 2019","volume":"94","author":"J Huang","year":"2022","journal-title":"J Med Virol"},{"issue":"6","key":"ppat.1013983.ref006","doi-asserted-by":"crossref","first-page":"380","DOI":"10.7326\/M18-2347","article-title":"A Cost-Effectiveness Analysis of Vaccination for Prevention of Herpes Zoster and Related Complications: Input for National Recommendations","volume":"170","author":"LA Prosser","year":"2019","journal-title":"Ann Intern Med"},{"issue":"31","key":"ppat.1013983.ref007","doi-asserted-by":"crossref","first-page":"4401","DOI":"10.1016\/j.vaccine.2019.06.008","article-title":"Effectiveness of the herpes zoster vaccine Zostavax\u00ae in Stockholm County, Sweden","volume":"37","author":"K Blom","year":"2019","journal-title":"Vaccine"},{"issue":"1","key":"ppat.1013983.ref008","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1093\/aje\/kwx245","article-title":"Long-Term Effectiveness of the Live Zoster Vaccine in Preventing Shingles: A Cohort Study","volume":"187","author":"R Baxter","year":"2018","journal-title":"Am J Epidemiol"},{"issue":"9","key":"ppat.1013983.ref009","doi-asserted-by":"crossref","first-page":"988","DOI":"10.1016\/S1473-3099(19)30163-X","article-title":"Immunogenicity and safety of the adjuvanted recombinant zoster vaccine in adults with haematological malignancies: a phase 3, randomised, clinical trial and post-hoc efficacy analysis","volume":"19","author":"AF Dagnew","year":"2019","journal-title":"Lancet Infect Dis"},{"issue":"8","key":"ppat.1013983.ref010","doi-asserted-by":"crossref","first-page":"1459","DOI":"10.1093\/cid\/ciab629","article-title":"The Adjuvanted Recombinant Zoster Vaccine Confers Long-Term Protection Against Herpes Zoster: Interim Results of an Extension Study of the Pivotal Phase 3 Clinical Trials ZOE-50 and ZOE-70","volume":"74","author":"C Boutry","year":"2022","journal-title":"Clin Infect Dis"},{"issue":"7456","key":"ppat.1013983.ref011","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1038\/nature12202","article-title":"Self-assembling influenza nanoparticle vaccines elicit broadly neutralizing H1N1 antibodies","volume":"499","author":"M Kanekiyo","year":"2013","journal-title":"Nature"},{"issue":"5","key":"ppat.1013983.ref012","article-title":"Two-component spike nanoparticle vaccine protects macaques from SARS-CoV-2 infection","volume":"184","author":"PJM Brouwer","year":"2021","journal-title":"Cell"},{"issue":"7855","key":"ppat.1013983.ref013","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/s41586-021-03365-x","article-title":"Quadrivalent influenza nanoparticle vaccines induce broad protection","volume":"592","author":"S Boyoglu-Barnum","year":"2021","journal-title":"Nature"},{"issue":"6606","key":"ppat.1013983.ref014","doi-asserted-by":"crossref","DOI":"10.1126\/science.abq0839","article-title":"Mosaic RBD nanoparticles protect against challenge by diverse sarbecoviruses in animal models","volume":"377","author":"AA Cohen","year":"2022","journal-title":"Science"},{"issue":"3","key":"ppat.1013983.ref015","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1080\/14760584.2019.1578216","article-title":"Immunological basis for enhanced immunity of nanoparticle vaccines","volume":"18","author":"HG Kelly","year":"2019","journal-title":"Expert Rev Vaccines"},{"issue":"1","key":"ppat.1013983.ref016","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1038\/s41541-021-00330-7","article-title":"Protein-based antigen presentation platforms for nanoparticle vaccines","volume":"6","author":"B Nguyen","year":"2021","journal-title":"NPJ Vaccines"},{"issue":"6","key":"ppat.1013983.ref017","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2019.01.046","article-title":"Induction of Potent Neutralizing Antibody Responses by a Designed Protein Nanoparticle Vaccine for Respiratory Syncytial Virus","volume":"176","author":"J Marcandalli","year":"2019","journal-title":"Cell"},{"key":"ppat.1013983.ref018","doi-asserted-by":"crossref","first-page":"1419634","DOI":"10.3389\/fimmu.2024.1419634","article-title":"A nanoparticle vaccine displaying varicella-zoster virus gE antigen induces a superior cellular immune response than a licensed vaccine in mice and non-human primates","volume":"15","author":"Y Li","year":"2024","journal-title":"Front Immunol"},{"key":"ppat.1013983.ref019","article-title":"Nanobody-based combination vaccine using licensed protein nanoparticles protects animals against respiratory and viral infections","author":"T Li","year":"2025","journal-title":"Nat Biomed Eng"},{"issue":"22","key":"ppat.1013983.ref020","doi-asserted-by":"crossref","first-page":"2893","DOI":"10.1016\/j.vaccine.2004.11.064","article-title":"A bacterially expressed particulate hepatitis E vaccine: antigenicity, immunogenicity and protectivity on primates","volume":"23","author":"SW Li","year":"2005","journal-title":"Vaccine"},{"issue":"10429","key":"ppat.1013983.ref021","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(23)02234-1","article-title":"Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"S Huang","year":"2024","journal-title":"Lancet"},{"issue":"3","key":"ppat.1013983.ref022","doi-asserted-by":"crossref","DOI":"10.1128\/JVI.01375-18","article-title":"Reactivation of Simian Varicella Virus in Rhesus Macaques after CD4 T Cell Depletion","volume":"93","author":"V Traina-Dorge","year":"2019","journal-title":"J Virol"},{"issue":"11","key":"ppat.1013983.ref023","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1002367","article-title":"CD4 T cell immunity is critical for the control of simian varicella virus infection in a nonhuman primate model of VZV infection","volume":"7","author":"K Haberthur","year":"2011","journal-title":"PLoS Pathog"},{"issue":"1","key":"ppat.1013983.ref024","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/s12877-017-0420-9","article-title":"The temporal impact of aging on the burden of herpes zoster","volume":"17","author":"L Varghese","year":"2017","journal-title":"BMC Geriatr"},{"key":"ppat.1013983.ref025","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jiab387","article-title":"Herpes Zoster Vaccines","volume":"224","author":"R Harbecke","year":"2021","journal-title":"J Infect Dis"},{"issue":"2","key":"ppat.1013983.ref026","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1086\/653605","article-title":"Zoster vaccine: current status and future prospects","volume":"51","author":"MN Oxman","year":"2010","journal-title":"Clin Infect Dis"},{"issue":"11","key":"ppat.1013983.ref027","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older","volume":"217","author":"AL Cunningham","year":"2018","journal-title":"J Infect Dis"},{"issue":"23","key":"ppat.1013983.ref028","doi-asserted-by":"crossref","DOI":"10.1172\/JCI172634","article-title":"Recruitment of naive CD4+ T cells by the recombinant zoster vaccine correlates with persistent immunity","volume":"133","author":"KJ Laing","year":"2023","journal-title":"J Clin Invest"},{"issue":"1","key":"ppat.1013983.ref029","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41541-022-00467-z","article-title":"An adjuvanted zoster vaccine elicits potent cellular immune responses in mice without QS21","volume":"7","author":"HJ Nam","year":"2022","journal-title":"NPJ Vaccines"},{"issue":"11","key":"ppat.1013983.ref030","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1093\/infdis\/jiy095","article-title":"Immune Responses to a Recombinant Glycoprotein E Herpes Zoster Vaccine in Adults Aged 50 Years or Older","volume":"217","author":"AL Cunningham","year":"2018","journal-title":"J Infect Dis"},{"issue":"12","key":"ppat.1013983.ref031","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/s41578-021-00358-0","article-title":"Lipid nanoparticles for mRNA delivery","volume":"6","author":"X Hou","year":"2021","journal-title":"Nat Rev Mater"},{"issue":"12","key":"ppat.1013983.ref032","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.3390\/vaccines12121335","article-title":"Advancements in Nanoparticle-Based Adjuvants for Enhanced Tuberculosis Vaccination: A Review","volume":"12","author":"J Wang","year":"2024","journal-title":"Vaccines (Basel)"},{"issue":"4","key":"ppat.1013983.ref033","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/j.immuni.2024.03.015","article-title":"Vaccine adjuvants: Tailoring innate recognition to send the right message","volume":"57","author":"EC Lavelle","year":"2024","journal-title":"Immunity"},{"issue":"9","key":"ppat.1013983.ref034","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1128\/CVI.00164-10","article-title":"Poly(anhydride) nanoparticles act as active Th1 adjuvants through Toll-like receptor exploitation","volume":"17","author":"I Tamayo","year":"2010","journal-title":"Clin Vaccine Immunol"},{"issue":"12","key":"ppat.1013983.ref035","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/infdis\/jit365","article-title":"Safety and immunogenicity of an AS01-adjuvanted varicella-zoster virus subunit candidate vaccine against herpes zoster in adults >=50 years of age","volume":"208","author":"R Chlibek","year":"2013","journal-title":"J Infect Dis"},{"issue":"10","key":"ppat.1013983.ref036","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.1093\/infdis\/jiaa421","article-title":"A Phase IIa Controlled Human Malaria Infection and Immunogenicity Study of RTS,S\/AS01E and RTS,S\/AS01B Delayed Fractional Dose Regimens in Malaria-Naive Adults","volume":"222","author":"JE Moon","year":"2020","journal-title":"J Infect Dis"},{"issue":"3","key":"ppat.1013983.ref037","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1086\/600120","article-title":"Randomized, double-blind, phase 2a trial of falciparum malaria vaccines RTS,S\/AS01B and RTS,S\/AS02A in malaria-naive adults: safety, efficacy, and immunologic associates of protection","volume":"200","author":"KE Kester","year":"2009","journal-title":"J Infect Dis"},{"issue":"6","key":"ppat.1013983.ref038","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1093\/infdis\/jiac327","article-title":"Safety and Immunogenicity of a Respiratory Syncytial Virus Prefusion F (RSVPreF3) Candidate Vaccine in Older Adults: Phase 1\/2 Randomized Clinical Trial","volume":"227","author":"I Leroux-Roels","year":"2023","journal-title":"J Infect Dis"},{"issue":"10429","key":"ppat.1013983.ref039","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/S0140-6736(23)02234-1","article-title":"Long-term efficacy of a recombinant hepatitis E vaccine in adults: 10-year results from a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"403","author":"S Huang","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"ppat.1013983.ref040","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.addr.2012.05.012","article-title":"Nanoparticle mediated non-covalent drug delivery","volume":"65","author":"T Doane","year":"2013","journal-title":"Adv Drug Deliv Rev"},{"issue":"6","key":"ppat.1013983.ref041","doi-asserted-by":"crossref","first-page":"5994","DOI":"10.3390\/ijms24065994","article-title":"NANOBODIES\u00ae: A Review of Diagnostic and Therapeutic Applications","volume":"24","author":"B-K Jin","year":"2023","journal-title":"Int J Mol Sci"},{"issue":"5","key":"ppat.1013983.ref042","doi-asserted-by":"crossref","first-page":"4166","DOI":"10.1021\/nn4055732","article-title":"In vivo architectonic stability of fully de novo designed protein-only nanoparticles","volume":"8","author":"MV C\u00e9spedes","year":"2014","journal-title":"ACS Nano"},{"issue":"52","key":"ppat.1013983.ref043","doi-asserted-by":"crossref","first-page":"26933","DOI":"10.1073\/pnas.1916028116","article-title":"Viral neutralization by antibody-imposed physical disruption","volume":"116","author":"Q Zheng","year":"2019","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"ppat.1013983.ref044","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1038\/cr.2015.34","article-title":"Structural basis for the neutralization of hepatitis E virus by a cross-genotype antibody","volume":"25","author":"Y Gu","year":"2015","journal-title":"Cell Res"},{"issue":"1","key":"ppat.1013983.ref045","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.bbrc.2020.07.074","article-title":"The crystal structure of the emerging human-infecting hepatitis E virus E2s protein","volume":"532","author":"C Bai","year":"2020","journal-title":"Biochem Biophys Res Commun"},{"issue":"43","key":"ppat.1013983.ref046","doi-asserted-by":"crossref","first-page":"50682","DOI":"10.1021\/acsami.1c12646","article-title":"Self-Assembly Dual-Responsive NO Donor Nanoparticles for Effective Cancer Therapy","volume":"13","author":"G Gu","year":"2021","journal-title":"ACS Appl Mater Interfaces"},{"key":"ppat.1013983.ref047","doi-asserted-by":"crossref","first-page":"212726","DOI":"10.1016\/j.bioadv.2022.212726","article-title":"Immunotherapeutic nanoparticles: From autoimmune disease control to the development of vaccines","volume":"135","author":"R Mitarotonda","year":"2022","journal-title":"Biomater Adv"},{"issue":"10125","key":"ppat.1013983.ref048","first-page":"1000","article-title":"End of the road for daclizumab in multiple sclerosis","volume":"391","author":"The Lancet","year":"2018","journal-title":"Lancet"},{"issue":"2","key":"ppat.1013983.ref049","doi-asserted-by":"crossref","first-page":"92","DOI":"10.3390\/ph14020092","article-title":"Monoclonal Antibodies as Neurological Therapeutics","volume":"14","author":"P Gklinos","year":"2021","journal-title":"Pharmaceuticals (Basel)"},{"issue":"5","key":"ppat.1013983.ref050","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1586\/eci.09.31","article-title":"Monoclonal antibody-induced cytokine-release syndrome","volume":"5","author":"PJ Bugelski","year":"2009","journal-title":"Expert Rev Clin Immunol"},{"key":"ppat.1013983.ref051","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/978-1-4939-8958-4_1","article-title":"Human monoclonal antibodies: The benefits of humanization.","volume-title":"Human monoclonal antibodies: Methods and protocols","author":"H. Waldmann","year":"2019"},{"issue":"14","key":"ppat.1013983.ref052","doi-asserted-by":"crossref","first-page":"4304","DOI":"10.1111\/febs.15809","article-title":"Immunogenicity and humanization of single-domain antibodies","volume":"289","author":"MA Rossotti","year":"2022","journal-title":"FEBS J"},{"issue":"1","key":"ppat.1013983.ref053","doi-asserted-by":"crossref","first-page":"14820","DOI":"10.1038\/s41598-018-32986-y","article-title":"Humanization of Antibodies using a Statistical Inference Approach","volume":"8","author":"A Clavero-\u00c1lvarez","year":"2018","journal-title":"Sci Rep"},{"issue":"22","key":"ppat.1013983.ref054","doi-asserted-by":"crossref","first-page":"4041","DOI":"10.1093\/bioinformatics\/btab434","article-title":"Humanization of antibodies using a machine learning approach on large-scale repertoire data","volume":"37","author":"C Marks","year":"2021","journal-title":"Bioinformatics"},{"issue":"3","key":"ppat.1013983.ref055","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/s41422-022-00612-2","article-title":"A novel STING agonist-adjuvanted pan-sarbecovirus vaccine elicits potent and durable neutralizing antibody and T cell responses in mice, rabbits and NHPs","volume":"32","author":"Z Liu","year":"2022","journal-title":"Cell Res"},{"issue":"1","key":"ppat.1013983.ref056","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1186\/s12951-025-03423-w","article-title":"Immunogenicity and cellular response of a herpes zoster virus gEgI fusion protein adjuvanted with CpG-emulsion in mice","volume":"23","author":"S Zhang","year":"2025","journal-title":"J Nanobiotechnology"},{"issue":"3","key":"ppat.1013983.ref057","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jb\/mvv038","article-title":"Isolation and characterization of antigen-specific alpaca (Lama pacos) VHH antibodies by biopanning followed by high-throughput sequencing","volume":"158","author":"N Miyazaki","year":"2015","journal-title":"J Biochem"},{"issue":"8","key":"ppat.1013983.ref058","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.3390\/v14081785","article-title":"Baculovirus Display of Varicella-Zoster Virus Glycoprotein E Induces Robust Humoral and Cellular Immune Responses in Mice","volume":"14","author":"W Xue","year":"2022","journal-title":"Viruses"},{"issue":"43","key":"ppat.1013983.ref059","doi-asserted-by":"crossref","first-page":"5790","DOI":"10.1002\/smll.201501345","article-title":"High-Throughput Continuous Flow Production of Nanoscale Liposomes by Microfluidic Vertical Flow Focusing","volume":"11","author":"RR Hood","year":"2015","journal-title":"Small"},{"issue":"1","key":"ppat.1013983.ref060","article-title":"Confocal Microscopy: Principles and Modern Practices","volume":"92","author":"AD Elliott","year":"2020","journal-title":"Curr Protoc Cytom"},{"issue":"2","key":"ppat.1013983.ref061","doi-asserted-by":"crossref","first-page":"519","DOI":"10.3390\/microorganisms11020519","article-title":"Current Methods for the Detection of Antibodies of Varicella-Zoster Virus: A Review","volume":"11","author":"D Pan","year":"2023","journal-title":"Microorganisms"},{"key":"ppat.1013983.ref062","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.jviromet.2014.01.014","article-title":"Development of a varicella-zoster virus neutralization assay using a glycoprotein K antibody enzyme-linked immunosorbent spot assay","volume":"200","author":"L Chen","year":"2014","journal-title":"J Virol Methods"},{"issue":"1","key":"ppat.1013983.ref063","doi-asserted-by":"crossref","DOI":"10.1002\/0471142735.im0624s78","article-title":"Detection of intracellular cytokines by flow cytometry","volume":"78","author":"B Foster","year":"2007","journal-title":"Current protocols in immunology"}],"updated-by":[{"DOI":"10.1371\/journal.ppat.1013983","type":"new_version","label":"New version","source":"publisher","updated":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T00:00:00Z","timestamp":1772755200000}}],"container-title":["PLOS Pathogens"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013983","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,6]],"date-time":"2026-03-06T18:54:34Z","timestamp":1772823274000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.ppat.1013983"}},"subtitle":[],"editor":[{"given":"Eain A","family":"Murphy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,3,2]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2026,3,2]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.ppat.1013983","relation":{},"ISSN":["1553-7374"],"issn-type":[{"value":"1553-7374","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,2]]}}}